JP2010535220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535220A5 JP2010535220A5 JP2010519954A JP2010519954A JP2010535220A5 JP 2010535220 A5 JP2010535220 A5 JP 2010535220A5 JP 2010519954 A JP2010519954 A JP 2010519954A JP 2010519954 A JP2010519954 A JP 2010519954A JP 2010535220 A5 JP2010535220 A5 JP 2010535220A5
- Authority
- JP
- Japan
- Prior art keywords
- antipsychotic
- combination
- olanzapine
- risperidone
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 37
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 33
- 230000000561 anti-psychotic effect Effects 0.000 claims description 32
- 229960005017 olanzapine Drugs 0.000 claims description 24
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 24
- 229960001534 risperidone Drugs 0.000 claims description 24
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 24
- -1 aboperidone Chemical compound 0.000 claims description 23
- 201000000980 schizophrenia Diseases 0.000 claims description 19
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 claims description 16
- 239000000164 antipsychotic agent Substances 0.000 claims description 14
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 12
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims description 12
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 claims description 12
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 12
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 12
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 claims description 12
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 claims description 12
- JNNOSTQEZICQQP-UHFFFAOYSA-N N-desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 claims description 12
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 claims description 12
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 claims description 12
- 229960003036 amisulpride Drugs 0.000 claims description 12
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 12
- 229960004372 aripiprazole Drugs 0.000 claims description 12
- 229960005245 asenapine Drugs 0.000 claims description 12
- 229950009087 bifeprunox Drugs 0.000 claims description 12
- 229950002871 blonanserin Drugs 0.000 claims description 12
- 229960004170 clozapine Drugs 0.000 claims description 12
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 12
- 229960002464 fluoxetine Drugs 0.000 claims description 12
- 229960003162 iloperidone Drugs 0.000 claims description 12
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 12
- LHAPOGAFBLSJJQ-GUTACTQSSA-N iti007 Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C([C@@H]1N2CCN(C=3C=CC=C(C2=3)[C@@H]1C1)C)CN1CCCC(=O)C1=CC=C(F)C=C1 LHAPOGAFBLSJJQ-GUTACTQSSA-N 0.000 claims description 12
- 229960001432 lurasidone Drugs 0.000 claims description 12
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims description 12
- 229960001861 melperone Drugs 0.000 claims description 12
- 229950010634 ocaperidone Drugs 0.000 claims description 12
- 229960001057 paliperidone Drugs 0.000 claims description 12
- 229950004193 perospirone Drugs 0.000 claims description 12
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 claims description 12
- 229960004431 quetiapine Drugs 0.000 claims description 12
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 12
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 12
- 229940034173 symbyax Drugs 0.000 claims description 12
- 229960000607 ziprasidone Drugs 0.000 claims description 12
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 12
- 229960004496 zotepine Drugs 0.000 claims description 12
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 229940005529 antipsychotics Drugs 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 230000007370 cognitive improvement Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 238000002648 combination therapy Methods 0.000 description 6
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 229960000762 perphenazine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- 229960001374 fluphenazine decanoate Drugs 0.000 description 2
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 229960000423 loxapine Drugs 0.000 description 2
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- 229960000652 sertindole Drugs 0.000 description 2
- 229960005013 tiotixene Drugs 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- BXDAOUXDMHXPDI-UHFFFAOYSA-N trifluoperazine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 BXDAOUXDMHXPDI-UHFFFAOYSA-N 0.000 description 2
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 2
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- BATFHSIVMJJJAF-UHFFFAOYSA-N Morindone Chemical compound OC1=CC=C2C(=O)C3=C(O)C(C)=CC=C3C(=O)C2=C1O BATFHSIVMJJJAF-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960004141 zuclopenthixol Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007129567/15A RU2508106C2 (ru) | 2007-08-01 | 2007-08-01 | Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии |
| RU2007129568/15A RU2508096C2 (ru) | 2007-08-01 | 2007-08-01 | Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии |
| PCT/US2008/009357 WO2009017836A1 (en) | 2007-08-01 | 2008-08-01 | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010535220A JP2010535220A (ja) | 2010-11-18 |
| JP2010535220A5 true JP2010535220A5 (enExample) | 2011-09-15 |
Family
ID=40304696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519954A Pending JP2010535220A (ja) | 2007-08-01 | 2008-08-01 | 抗精神病用の併用療法剤を使用する統合失調症の治療のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110269777A1 (enExample) |
| EP (1) | EP2175724A4 (enExample) |
| JP (1) | JP2010535220A (enExample) |
| KR (1) | KR20100054812A (enExample) |
| CN (1) | CN101842010A (enExample) |
| AU (1) | AU2008282742A1 (enExample) |
| BR (1) | BRPI0815850A2 (enExample) |
| CA (1) | CA2719824A1 (enExample) |
| MX (1) | MX2010001218A (enExample) |
| WO (1) | WO2009017836A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7837812B2 (en) | 2004-05-21 | 2010-11-23 | Ati Properties, Inc. | Metastable beta-titanium alloys and methods of processing the same by direct aging |
| CN101868234A (zh) | 2007-09-20 | 2010-10-20 | D2E有限公司 | 具有神经保护和认知增强特性的氢化吡啶并[4,3-b]吲哚的含氟衍生物,其制备方法及应用 |
| RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| RU2544856C2 (ru) * | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| BRPI0906245A2 (pt) | 2008-03-24 | 2015-06-30 | Medivation Technologies Inc | Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit |
| WO2009120717A2 (en) | 2008-03-24 | 2009-10-01 | Medivation Technologies, Inc. | Pyrido [3, 4-b] indoles and methods of use |
| CN105168219B (zh) | 2008-05-27 | 2018-11-20 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| CN102271508B (zh) | 2008-10-31 | 2015-04-29 | 梅迪维新技术公司 | 含有刚性部分的吡啶并[4，3-b]吲哚类化合物 |
| EP2348847A4 (en) | 2008-10-31 | 2012-05-23 | Medivation Technologies Inc | AZEPINO [4, 5-B] INDOLE AND USE PROCESS |
| SG173639A1 (en) | 2009-02-11 | 2011-09-29 | Sunovion Pharmaceuticals Inc | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| CN103145707B (zh) * | 2009-04-10 | 2016-05-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 氢化吡啶[4,3-b]吲哚类化合物的制备方法 |
| CN102480956B (zh) | 2009-04-29 | 2015-04-08 | 梅迪维新技术公司 | 吡啶并[4,3-b]吲哚类和使用方法 |
| WO2010127177A1 (en) | 2009-04-29 | 2010-11-04 | Medivation Technologies, Inc. | Pyrido [4,3-b] indoles and methods of use |
| CN102711466A (zh) | 2009-09-23 | 2012-10-03 | 梅迪维新技术公司 | 桥连杂环化合物及其使用方法 |
| BR112012006646A2 (pt) | 2009-09-23 | 2019-09-24 | Medivation Technologies Inc | composto, composição farmacêutica, método de tratamento de um distùrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit |
| CA2775328A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| WO2011103485A1 (en) * | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| WO2011103448A1 (en) * | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Methods and compositions for treating psychotic disorders using antipsychotic combination therapy |
| MX345230B (es) | 2010-02-24 | 2017-01-20 | The Broad Inst Inc * | Metodos para diagnosticar patogenos de enfermedad infecciosa y su sensibilidad a farmacos. |
| US20140303144A1 (en) | 2011-02-18 | 2014-10-09 | Medivation Technologies, Inc. | Compounds and methods of treating hypertension |
| WO2012112963A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| CN103476416B (zh) | 2011-02-18 | 2016-09-21 | 梅迪维新技术公司 | 治疗高血压的化合物和方法 |
| US20150224120A1 (en) * | 2011-09-14 | 2015-08-13 | Catherine Clelland | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| MX2014012374A (es) | 2012-04-14 | 2015-04-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2014128882A1 (ja) * | 2013-02-21 | 2014-08-28 | 医療法人 和楽会 | 不安うつ病の治療薬 |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3076967B1 (en) | 2013-12-03 | 2021-07-28 | Intra-Cellular Therapies, Inc. | Methods for treating residual symptoms of schizophrenia |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR101646962B1 (ko) | 2014-09-29 | 2016-08-10 | 한국과학기술연구원 | CaM 저해활성을 가지는 페노싸이아진 유도체 |
| US20160184290A1 (en) * | 2014-12-31 | 2016-06-30 | Paul J. Markovitz | Method of treating schizophrenia |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| WO2016205631A1 (en) * | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders |
| RU2743513C2 (ru) | 2016-01-26 | 2021-02-19 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| JP6686168B2 (ja) | 2016-03-25 | 2020-04-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| EP3436016B1 (en) | 2016-03-28 | 2022-04-27 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
| WO2017172784A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
| KR102506333B1 (ko) | 2016-12-20 | 2023-03-06 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀을 함유하는 경피흡수 치료 시스템 |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
| CA3045043A1 (en) | 2016-12-31 | 2018-07-05 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| MX387784B (es) | 2017-03-24 | 2025-03-18 | Intra Celular Therapies Inc | Composiciones novedosas y metodos. |
| US10035795B1 (en) | 2017-04-06 | 2018-07-31 | Korea Institute Of Science And Technology | Phenothiazine derivatives having CaM inhibitory activity |
| EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
| CA3071137A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Prodrugs of substituted heterocycle fused gamma-carbolines |
| IL272249B2 (en) | 2017-07-26 | 2023-11-01 | Intra Cellular Therapies Inc | Organic compounds |
| JP2020535231A (ja) | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規な塩および結晶 |
| US11980617B2 (en) | 2018-03-16 | 2024-05-14 | Intra-Cellular Therapies, Inc. | Methods of treating acute depression and/or acute anxiety |
| CN112040940A (zh) | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
| EP3628007B1 (en) | 2018-06-06 | 2023-05-03 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| CA3102948A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CN115154440A (zh) | 2018-06-27 | 2022-10-11 | 比奥克斯塞尔医疗股份有限公司 | 含右美托咪定的膜制剂及其制造方法 |
| WO2020047241A1 (en) | 2018-08-29 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
| CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP7377871B2 (ja) | 2018-12-21 | 2023-11-10 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| CN114072150A (zh) | 2019-07-07 | 2022-02-18 | 细胞内治疗公司 | 新方法 |
| WO2021016112A2 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| EP4072554A4 (en) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUND |
| US20240139169A1 (en) * | 2021-02-26 | 2024-05-02 | Bioxcel Therapeutics, Inc. | Methods and compositions for treating agitation |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| CN115290775A (zh) * | 2022-07-25 | 2022-11-04 | 上海市徐汇区中心医院 | 一种精神类药物质控品、其试剂盒、制备方法及应用 |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS229067B1 (en) * | 1981-08-20 | 1984-04-16 | Svorad Stolc | Medicinal preparation with antiarhythmic and supporting effect applied with hypoxia,and method of preparing active substance thereof |
| US4672117A (en) * | 1985-09-16 | 1987-06-09 | American Home Products Corporation | Antipsychotic gamma-carbolines |
| US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
| US5631265A (en) * | 1994-03-11 | 1997-05-20 | Eli Lilly And Company | 8-substituted tetrahydro-beta-carbolines |
| RU2140417C1 (ru) * | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| TW470745B (en) * | 1996-05-23 | 2002-01-01 | Janssen Pharmaceutica Nv | Hexahydro-pyrido[4,3-b]indole derivatives |
| BR0211608A (pt) * | 2001-08-08 | 2006-04-04 | Upjohn Co | 1h-pirido[4,3-b]indóis terapêuticos |
| WO2005120463A1 (en) * | 2004-06-09 | 2005-12-22 | Ranbaxy Laboratories Limited | Rapidly disintegrating tablets of risperidone |
| WO2007041697A2 (en) * | 2005-10-04 | 2007-04-12 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
| US20070112017A1 (en) * | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| RU2338537C2 (ru) * | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| JP2010528016A (ja) * | 2007-05-25 | 2010-08-19 | メディベーション ニューロロジー， インコーポレイテッド | 細胞を刺激するための方法および組成物 |
-
2008
- 2008-08-01 EP EP08826868A patent/EP2175724A4/en not_active Withdrawn
- 2008-08-01 MX MX2010001218A patent/MX2010001218A/es not_active Application Discontinuation
- 2008-08-01 BR BRPI0815850-9A2A patent/BRPI0815850A2/pt not_active IP Right Cessation
- 2008-08-01 JP JP2010519954A patent/JP2010535220A/ja active Pending
- 2008-08-01 US US12/671,679 patent/US20110269777A1/en not_active Abandoned
- 2008-08-01 AU AU2008282742A patent/AU2008282742A1/en not_active Abandoned
- 2008-08-01 CA CA2719824A patent/CA2719824A1/en not_active Abandoned
- 2008-08-01 CN CN200880107277A patent/CN101842010A/zh active Pending
- 2008-08-01 KR KR1020107004429A patent/KR20100054812A/ko not_active Withdrawn
- 2008-08-01 WO PCT/US2008/009357 patent/WO2009017836A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535220A5 (enExample) | ||
| ES2623503T3 (es) | Composiciones para tratar náuseas y vómitos mediados centralmente | |
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| JP2009525343A5 (enExample) | ||
| CN105873576A (zh) | 治疗肥胖 | |
| JP2018523689A5 (enExample) | ||
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| CN108697678A (zh) | sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用 | |
| Fong et al. | Repurposing chloroquine analogs as an adjuvant cancer therapy | |
| Chave et al. | Henoch‐Schönlein purpura following hepatitis B vaccination | |
| CN105163806A (zh) | 左西替利嗪和孟鲁司特在治疗过敏反应中的用途 | |
| JP2008526927A5 (enExample) | ||
| US11612595B2 (en) | Compositions and methods for treating rheumatoid arthritis | |
| JP2013500943A5 (enExample) | ||
| EP3119388A1 (en) | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| JP5089687B2 (ja) | アルコール依存症または薬物依存症の予防または治療剤 | |
| AU2019304850B2 (en) | Benzoic acid or a salt thereof for use in preventing or treating anti-N-methyl-D-aspartate receptor encephalitis | |
| US20090163544A1 (en) | Use of NK-3 Receptor Antagonists for the Treatment of Nausea and Vomiting | |
| EP1667719A1 (en) | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin | |
| JP2009501205A (ja) | 精神病治療用組成物 | |
| CN110891574A (zh) | 用于预防和/或治疗肝细胞癌的美格列明 | |
| HK40041658A (en) | Benzoic acid or a salt thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis | |
| US20170020867A1 (en) | Use of masitinib for the treatment of crohn's disease | |
| JP2006516267A5 (enExample) |